Georgios Vlasakakis

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Lina Keutzer, Huifang You, Ali Farnoud et al. · Pharmaceutics · 2022 · 87 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Andreas H. Diacon, Clifton E. Barry, Alex Carlton et al. · Nature Medicine · 2024 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

Paolo Pozzilli, Emanuele Bosi, Deborah T. Cirkel et al. · The Journal of Clinical Endocrinology & Metabolism · 2020 · 44 citations · Full text

Medicine, Endocrinology, Pharmacology +15

White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and Simulation

Georgios Vlasakakis, Emmanuelle Comets, Anne Keunecke et al. · CPT Pharmacometrics & Systems Pharmacology · 2013 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients

Georgios Vlasakakis, Antonella Napolitano, Ruth M. Barnard et al. · British Journal of Clinical Pharmacology · 2018 · 12 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15